Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines–Heart Failure (GWTG-HF)

Nancy Luo, Gregg C. Fonarow, Steven J. Lippmann, Xiaojuan Mi, Paul A. Heidenreich, Clyde W. Yancy, Melissa A. Greiner, Bradley G. Hammill, N. Chantelle Hardy, Stuart J. Turner, Warren K. Laskey, Lesley H. Curtis, Adrian F. Hernandez, Robert J. Mentz, Emily C. O'Brien

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Objectives The aim of this study was to assess the prevalence and variation in angiotensin receptor/neprilysin inhibitor (ARNI) prescription among a real-world population with heart failure with reduced ejection fraction (HFrEF). Background The U.S. Food and Drug Administration approved sacubitril/valsartan for patients with HFrEF in July 2015. Little is known about the early patterns of use of this novel therapy. Methods The study included patients discharged alive from hospitals in Get With the Guidelines–Heart Failure (GWTG-HF), a registry of hospitalized patients with heart failure, between July 2015 and June 2016 who had documentation of whether ARNIs were prescribed at discharge. Patient and hospital characteristics were compared among patients with HFrEF (ejection fraction ≤40%) with and without ARNI prescription at discharge, excluding those with documented contraindications to ARNIs. To evaluate hospital variation, hospitals with at least 10 eligible hospitalizations during the study period were assessed. Results Of 21,078 patients hospitalized with HFrEF during the study period, 495 (2.3%) were prescribed ARNIs at discharge. Patients prescribed ARNIs were younger (median age 65 years vs. 70 years; p < 0.001), had lower ejection fractions (median 23% vs. 25%; p < 0.001), and had higher use of aldosterone antagonists (45% vs. 31%; p < 0.001) at discharge. At the 241 participating hospitals with 10 or more eligible admissions, 125 (52%) reported no discharge prescriptions of ARNIs. Conclusions Approximately 2.3% of patients hospitalized for HFrEF in a national registry were prescribed ARNI therapy in the first 12 months following Food and Drug Administration approval. Further study is needed to identify and overcome barriers to implementing new evidence into practice, such as ARNI use among eligible patients with HFrEF.

Original languageEnglish (US)
Pages (from-to)305-309
Number of pages5
JournalJACC: Heart Failure
Volume5
Issue number4
DOIs
StatePublished - Apr 1 2017
Externally publishedYes

Fingerprint

Heart Failure
Neprilysin
Angiotensin Receptors
Prescriptions
United States Food and Drug Administration
Registries
Mineralocorticoid Receptor Antagonists
Drug Approval
LCZ 696
Documentation
Hospitalization
Therapeutics
Population

Keywords

  • early adoption
  • new therapy
  • sacubitril/valsartan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction : Insights From Get With the Guidelines–Heart Failure (GWTG-HF). / Luo, Nancy; Fonarow, Gregg C.; Lippmann, Steven J.; Mi, Xiaojuan; Heidenreich, Paul A.; Yancy, Clyde W.; Greiner, Melissa A.; Hammill, Bradley G.; Hardy, N. Chantelle; Turner, Stuart J.; Laskey, Warren K.; Curtis, Lesley H.; Hernandez, Adrian F.; Mentz, Robert J.; O'Brien, Emily C.

In: JACC: Heart Failure, Vol. 5, No. 4, 01.04.2017, p. 305-309.

Research output: Contribution to journalArticle

Luo, N, Fonarow, GC, Lippmann, SJ, Mi, X, Heidenreich, PA, Yancy, CW, Greiner, MA, Hammill, BG, Hardy, NC, Turner, SJ, Laskey, WK, Curtis, LH, Hernandez, AF, Mentz, RJ & O'Brien, EC 2017, 'Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines–Heart Failure (GWTG-HF)', JACC: Heart Failure, vol. 5, no. 4, pp. 305-309. https://doi.org/10.1016/j.jchf.2016.12.018
Luo, Nancy ; Fonarow, Gregg C. ; Lippmann, Steven J. ; Mi, Xiaojuan ; Heidenreich, Paul A. ; Yancy, Clyde W. ; Greiner, Melissa A. ; Hammill, Bradley G. ; Hardy, N. Chantelle ; Turner, Stuart J. ; Laskey, Warren K. ; Curtis, Lesley H. ; Hernandez, Adrian F. ; Mentz, Robert J. ; O'Brien, Emily C. / Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction : Insights From Get With the Guidelines–Heart Failure (GWTG-HF). In: JACC: Heart Failure. 2017 ; Vol. 5, No. 4. pp. 305-309.
@article{876112fcfb64404a84f4895e7b388cbb,
title = "Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines–Heart Failure (GWTG-HF)",
abstract = "Objectives The aim of this study was to assess the prevalence and variation in angiotensin receptor/neprilysin inhibitor (ARNI) prescription among a real-world population with heart failure with reduced ejection fraction (HFrEF). Background The U.S. Food and Drug Administration approved sacubitril/valsartan for patients with HFrEF in July 2015. Little is known about the early patterns of use of this novel therapy. Methods The study included patients discharged alive from hospitals in Get With the Guidelines–Heart Failure (GWTG-HF), a registry of hospitalized patients with heart failure, between July 2015 and June 2016 who had documentation of whether ARNIs were prescribed at discharge. Patient and hospital characteristics were compared among patients with HFrEF (ejection fraction ≤40{\%}) with and without ARNI prescription at discharge, excluding those with documented contraindications to ARNIs. To evaluate hospital variation, hospitals with at least 10 eligible hospitalizations during the study period were assessed. Results Of 21,078 patients hospitalized with HFrEF during the study period, 495 (2.3{\%}) were prescribed ARNIs at discharge. Patients prescribed ARNIs were younger (median age 65 years vs. 70 years; p < 0.001), had lower ejection fractions (median 23{\%} vs. 25{\%}; p < 0.001), and had higher use of aldosterone antagonists (45{\%} vs. 31{\%}; p < 0.001) at discharge. At the 241 participating hospitals with 10 or more eligible admissions, 125 (52{\%}) reported no discharge prescriptions of ARNIs. Conclusions Approximately 2.3{\%} of patients hospitalized for HFrEF in a national registry were prescribed ARNI therapy in the first 12 months following Food and Drug Administration approval. Further study is needed to identify and overcome barriers to implementing new evidence into practice, such as ARNI use among eligible patients with HFrEF.",
keywords = "early adoption, new therapy, sacubitril/valsartan",
author = "Nancy Luo and Fonarow, {Gregg C.} and Lippmann, {Steven J.} and Xiaojuan Mi and Heidenreich, {Paul A.} and Yancy, {Clyde W.} and Greiner, {Melissa A.} and Hammill, {Bradley G.} and Hardy, {N. Chantelle} and Turner, {Stuart J.} and Laskey, {Warren K.} and Curtis, {Lesley H.} and Hernandez, {Adrian F.} and Mentz, {Robert J.} and O'Brien, {Emily C.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.jchf.2016.12.018",
language = "English (US)",
volume = "5",
pages = "305--309",
journal = "JACC: Heart Failure",
issn = "2213-1779",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction

T2 - Insights From Get With the Guidelines–Heart Failure (GWTG-HF)

AU - Luo, Nancy

AU - Fonarow, Gregg C.

AU - Lippmann, Steven J.

AU - Mi, Xiaojuan

AU - Heidenreich, Paul A.

AU - Yancy, Clyde W.

AU - Greiner, Melissa A.

AU - Hammill, Bradley G.

AU - Hardy, N. Chantelle

AU - Turner, Stuart J.

AU - Laskey, Warren K.

AU - Curtis, Lesley H.

AU - Hernandez, Adrian F.

AU - Mentz, Robert J.

AU - O'Brien, Emily C.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Objectives The aim of this study was to assess the prevalence and variation in angiotensin receptor/neprilysin inhibitor (ARNI) prescription among a real-world population with heart failure with reduced ejection fraction (HFrEF). Background The U.S. Food and Drug Administration approved sacubitril/valsartan for patients with HFrEF in July 2015. Little is known about the early patterns of use of this novel therapy. Methods The study included patients discharged alive from hospitals in Get With the Guidelines–Heart Failure (GWTG-HF), a registry of hospitalized patients with heart failure, between July 2015 and June 2016 who had documentation of whether ARNIs were prescribed at discharge. Patient and hospital characteristics were compared among patients with HFrEF (ejection fraction ≤40%) with and without ARNI prescription at discharge, excluding those with documented contraindications to ARNIs. To evaluate hospital variation, hospitals with at least 10 eligible hospitalizations during the study period were assessed. Results Of 21,078 patients hospitalized with HFrEF during the study period, 495 (2.3%) were prescribed ARNIs at discharge. Patients prescribed ARNIs were younger (median age 65 years vs. 70 years; p < 0.001), had lower ejection fractions (median 23% vs. 25%; p < 0.001), and had higher use of aldosterone antagonists (45% vs. 31%; p < 0.001) at discharge. At the 241 participating hospitals with 10 or more eligible admissions, 125 (52%) reported no discharge prescriptions of ARNIs. Conclusions Approximately 2.3% of patients hospitalized for HFrEF in a national registry were prescribed ARNI therapy in the first 12 months following Food and Drug Administration approval. Further study is needed to identify and overcome barriers to implementing new evidence into practice, such as ARNI use among eligible patients with HFrEF.

AB - Objectives The aim of this study was to assess the prevalence and variation in angiotensin receptor/neprilysin inhibitor (ARNI) prescription among a real-world population with heart failure with reduced ejection fraction (HFrEF). Background The U.S. Food and Drug Administration approved sacubitril/valsartan for patients with HFrEF in July 2015. Little is known about the early patterns of use of this novel therapy. Methods The study included patients discharged alive from hospitals in Get With the Guidelines–Heart Failure (GWTG-HF), a registry of hospitalized patients with heart failure, between July 2015 and June 2016 who had documentation of whether ARNIs were prescribed at discharge. Patient and hospital characteristics were compared among patients with HFrEF (ejection fraction ≤40%) with and without ARNI prescription at discharge, excluding those with documented contraindications to ARNIs. To evaluate hospital variation, hospitals with at least 10 eligible hospitalizations during the study period were assessed. Results Of 21,078 patients hospitalized with HFrEF during the study period, 495 (2.3%) were prescribed ARNIs at discharge. Patients prescribed ARNIs were younger (median age 65 years vs. 70 years; p < 0.001), had lower ejection fractions (median 23% vs. 25%; p < 0.001), and had higher use of aldosterone antagonists (45% vs. 31%; p < 0.001) at discharge. At the 241 participating hospitals with 10 or more eligible admissions, 125 (52%) reported no discharge prescriptions of ARNIs. Conclusions Approximately 2.3% of patients hospitalized for HFrEF in a national registry were prescribed ARNI therapy in the first 12 months following Food and Drug Administration approval. Further study is needed to identify and overcome barriers to implementing new evidence into practice, such as ARNI use among eligible patients with HFrEF.

KW - early adoption

KW - new therapy

KW - sacubitril/valsartan

UR - http://www.scopus.com/inward/record.url?scp=85016561109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016561109&partnerID=8YFLogxK

U2 - 10.1016/j.jchf.2016.12.018

DO - 10.1016/j.jchf.2016.12.018

M3 - Article

C2 - 28359417

AN - SCOPUS:85016561109

VL - 5

SP - 305

EP - 309

JO - JACC: Heart Failure

JF - JACC: Heart Failure

SN - 2213-1779

IS - 4

ER -